Nabriva Therapeutics plc
NBRVF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $2,548 | $1,647 | $488 | $282 |
| - Cash | $12,414 | $47,659 | $41,359 | $86,019 |
| + Debt | $5,221 | $8,030 | $7,727 | $34,502 |
| Enterprise Value | -$4,645 | -$37,982 | -$33,144 | -$51,235 |
| Revenue | $35,668 | $27,216 | $5,027 | $7,748 |
| % Growth | 31.1% | 441.4% | -35.1% | – |
| Gross Profit | $7,087 | $14,068 | $3,441 | $7,678 |
| % Margin | 19.9% | 51.7% | 68.5% | 99.1% |
| EBITDA | -$54,702 | -$47,422 | -$66,876 | -$78,719 |
| % Margin | -153.4% | -174.2% | -1,330.3% | -1,016% |
| Net Income | -$57,185 | -$49,450 | -$69,484 | -$82,764 |
| % Margin | -160.3% | -181.7% | -1,382.2% | -1,068.2% |
| EPS Diluted | -21.32 | -28.52 | -135.23 | -278.75 |
| % Growth | 25.2% | 78.9% | 51.5% | – |
| Operating Cash Flow | -$36,711 | -$59,557 | -$71,331 | -$71,892 |
| Capital Expenditures | -$211 | -$25 | -$113 | -$61 |
| Free Cash Flow | -$36,922 | -$59,582 | -$71,444 | -$71,953 |